What's in Universiteit Antwerpen's pipeline?

Universiteit Antwerpen has 4 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Universiteit Antwerpen's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/universiteit-antwerpen.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Universiteit Antwerpen — Portfolio Competitive Intelligence Brief

Universiteit Antwerpen pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Area
Quinvaxem	Quinvaxem	marketed	Other
mRNA-1273 100µg	mRNA-1273 100µg	marketed
Lactobacillus casei Shirota	Lactobacillus casei Shirota	marketed

Therapeutic area mix

Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Universiteit Antwerpen:

Cite this brief

Drug Landscape (2026). Universiteit Antwerpen — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universiteit-antwerpen. Accessed 2026-05-16.